DPLPharmaceuticals
Dipna Pharmachem Ltd — Balance Sheet
₹8.02
-2.59%
Dipna Pharmachem Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Ordinary Shares Number | 2.40 Cr | 2.40 Cr | 1.46 Cr | 1.46 Cr | — |
| Share Issued | 2.40 Cr | 2.40 Cr | 1.46 Cr | 1.46 Cr | — |
| Net Debt | 16.80 Cr | 5.57 Cr | 10.22 Cr | 9.98 Cr | — |
| Total Debt | 17.22 Cr | 19.45 Cr | 15.91 Cr | 10.19 Cr | — |
| Tangible Book Value | 38.49 Cr | 37.52 Cr | 24.36 Cr | 1.74 Cr | — |
| Invested Capital | 55.72 Cr | 56.96 Cr | 40.27 Cr | 11.93 Cr | — |
| Working Capital | 47.33 Cr | 50.03 Cr | 35.29 Cr | 7.50 Cr | — |
| Net Tangible Assets | 38.49 Cr | 37.52 Cr | 24.36 Cr | 1.74 Cr | — |
| Common Stock Equity | 38.49 Cr | 37.52 Cr | 24.36 Cr | 1.74 Cr | — |
| Total Capitalization | 47.38 Cr | 50.07 Cr | 35.33 Cr | 7.54 Cr | — |
| Total Equity Gross Minority Interest | 38.49 Cr | 37.52 Cr | 24.36 Cr | 1.74 Cr | — |
| Stockholders Equity | 38.49 Cr | 37.52 Cr | 24.36 Cr | 1.74 Cr | — |
| Capital Stock | 24.05 Cr | 24.05 Cr | 11.97 Cr | 0.04 Cr | — |
| Common Stock | 24.05 Cr | 24.05 Cr | 11.97 Cr | 0.04 Cr | — |
| Total Liabilities Net Minority Interest | 93.89 Cr | 95.39 Cr | 53.20 Cr | 34.49 Cr | — |
| Total Non Current Liabilities Net Minority Interest | 8.89 Cr | 12.55 Cr | 10.97 Cr | 5.80 Cr | — |
| Non Current Deferred Taxes Liabilities | 0.00 | 0.00 | 0.00 | — | — |
| Long Term Debt And Capital Lease Obligation | 8.89 Cr | 12.55 Cr | 10.97 Cr | 5.80 Cr | — |
| Long Term Debt | 8.89 Cr | 12.55 Cr | 10.97 Cr | 5.80 Cr | — |
| Current Liabilities | 85.00 Cr | 82.84 Cr | 42.23 Cr | 28.69 Cr | — |
| Other Current Liabilities | 0.40 Cr | 0.20 Cr | 0.14 Cr | 0.87 Cr | — |
| Current Debt And Capital Lease Obligation | 8.33 Cr | 6.90 Cr | 4.94 Cr | 4.39 Cr | — |
| Current Debt | 8.33 Cr | 6.90 Cr | 4.94 Cr | 4.39 Cr | — |
| Current Provisions | 0.54 Cr | 1.21 Cr | 0.87 Cr | — | — |
| Payables | 75.73 Cr | 72.50 Cr | 35.38 Cr | 22.78 Cr | — |
| Accounts Payable | 75.73 Cr | 72.30 Cr | 35.24 Cr | 21.91 Cr | — |
| Total Assets | 132.38 Cr | 132.91 Cr | 77.56 Cr | 36.23 Cr | — |
| Total Non Current Assets | 0.05 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr | — |
| Other Non Current Assets | -1000.00 | — | -1000.00 | — | — |
| Non Current Deferred Taxes Assets | 29000.00 | 25000.00 | 6000.00 | 0.00 | — |
| Goodwill And Other Intangible Assets | 0.00 | 0.00 | 0.00 | — | — |
| Net PPE | 0.05 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr | — |
| Gross PPE | 0.05 Cr | 0.10 Cr | 0.09 Cr | 0.08 Cr | — |
| Construction In Progress | 0.00 | 0.00 | 0.00 | — | — |
| Other Properties | 0.05 Cr | 0.03 Cr | 0.02 Cr | 0.02 Cr | — |
| Current Assets | 132.33 Cr | 132.87 Cr | 77.52 Cr | 36.19 Cr | — |
| Other Current Assets | 58.19 Cr | 50.67 Cr | 24.35 Cr | — | — |
| Inventory | 27.43 Cr | 37.38 Cr | 18.94 Cr | 6.30 Cr | — |
| Accounts Receivable | 46.28 Cr | 30.94 Cr | 28.53 Cr | 26.97 Cr | — |
| Cash Cash Equivalents And Short Term Investments | 0.43 Cr | 13.88 Cr | 5.69 Cr | 0.21 Cr | — |
| Cash And Cash Equivalents | 0.43 Cr | 13.88 Cr | 5.69 Cr | 0.21 Cr | — |
| Retained Earnings | — | 2.15 Cr | 1.06 Cr | 1.48 Cr | 0.31 Cr |
| Additional Paid In Capital | — | 11.33 Cr | 11.33 Cr | 0.23 Cr | 0.23 Cr |
| Other Non Current Liabilities | — | -3000.00 | -1000.00 | — | — |
| Current Deferred Taxes Liabilities | — | 1.21 Cr | 0.87 Cr | 0.40 Cr | 0.01 Cr |
| Total Tax Payable | — | 0.20 Cr | 0.14 Cr | 0.87 Cr | — |
| Accumulated Depreciation | — | -0.07 Cr | -0.05 Cr | -0.04 Cr | -0.03 Cr |
| Machinery Furniture Equipment | — | 0.08 Cr | 0.07 Cr | 0.06 Cr | 0.06 Cr |
| Prepaid Assets | — | 6.37 Cr | 1.74 Cr | 2.69 Cr | 0.58 Cr |
| Finished Goods | — | 37.38 Cr | 18.94 Cr | 6.30 Cr | 7.20 Cr |
| Other Receivables | — | 44.30 Cr | 22.61 Cr | 0.01 Cr | 1.77 Cr |
| Cash Financial | — | 13.88 Cr | 5.69 Cr | 0.08 Cr | 0.13 Cr |
| Cash Equivalents | — | — | 0.00 | 0.13 Cr | 0.13 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Dipna Pharmachem Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.